Table 3.
Acute antiarrhythmic therapy—second regimen
| Monotherapy (n = 16) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Medication used | Route (IV) | IV starting dosage (mg/d) | IV maximum dosage (mg/d) | Route (PO) | PO starting dosage (mg/d) | PO maximum dosage (mg/d) | Adequate SVT control | |
| Digoxin | 5 (31.2%) | 1 (20.0%) | Not reported | Not reported | 4 (80.0%) | 0.031 (0.014-0.068) | 0.031 (0.014-0.068) | 4 (80.0%) |
| Esmolol | 3 (18.8%) | 3 (100%) | 72 (72-446.4) | 360 (108-669.6) | n/a | n/a | n/a | 1 (33.3%) |
| Flecainide | 2 (12.5%) | 1 (50.0%) | Not reported | Not reported | 1 (50.0%) | 24 | 24 | 1 (50.0%) |
| Propranolol | 4 (25.0%) | 1 (25.0%) | 1.14 | 1.5 | 3 (75.0%) | 2.628 (1.14-9) | 6.9 (1.5-14.68) | 2 (50.0%) |
| Sotalol | 1 (6.3%) | n/a | n/a | n/a | 1 (100%) | 15 | 15 | 1 (100%) |
| Procainamide | 1 (6.3%) | 1 (100%) | 28.8 | 28.8 | n/a | n/a | n/a | 1 (100%) |
| Adequate SVT control | 10 (62.5%) | |||||||
| Adverse events | 0 (0.0%) | |||||||
| Combination therapy (n = 16) | |||||||
|---|---|---|---|---|---|---|---|
| First medication | Medication route | starting dosage (mg/d) | Maximum dosage (mg/d) | Second medication | Medication route | starting dosage (mg/d) | Maximum dosage (mg/d) |
| Esmolol | IV | 144 | 504 | Amiodarone | IV | 7.2 | 21.6 |
| Propranolol | PO | Not reported | Not reported | Digoxin | Unspecified | Not reported | Not reported |
| Propranolol | PO | 12 | 12 | Digoxin | PO | 0.03 | 0.03 |
| Flecainide | PO | 10 | 10 | Propranolol | PO | 6.08 | 6.08 |
| Sotalol | PO | Not reported | Not reported | Flecainide | PO | Not reported | Not reported |
| Sotalol | PO | 27 | 27 | Digoxin | PO | 0.03 | 0.03 |
| Esmolol | IV | 72 | 504 | Sotalol | PO | 24 | 30 |
| Propranolol | PO | 7.5 | 11.28 | Flecainide | PO | 18 | 18 |
| Propranolol | PO | 8.31 | 8.31 | Flecainide | PO | 11.4 | 11.4 |
| Propranolol | PO | 1.5 | 1.5 | Digoxin | PO | 0.012 | 0.012 |
| Esmolol | IV | 144 | 144 | Sotalol | PO | 3 | 3 |
| Esmolol | IV | 72 | 72 | Propranolol | PO | 4.3 | 8.6 |
| Esmolol | IV | 446.4 | 446.4 | Flecainide | PO | 9.6 | 9.6 |
| Sotalol | PO | 2.85 | 3.8 | Sotalol | PO | Not reported | Not reported |
| Esmolol | IV | 648 | 648 | Sotalol | PO | 7.3 | 30 |
| Propranolol | PO | 12.8 | 19.2 | Procainamide | IV | 28.8 | 43.2 |
| Adequate SVT control | 9 (56.3%) | ||||||
| Adverse events | 3 (18.8%) | ||||||
Second treatment regimen attempted for patients in whom adequate SVT control was not achieved with the first regimen. Patients on combination therapy in whom adequate SVT control was not achieved are bolded. Dosages are reported as medians and ranges.
IV, intravenous route; n/a, not available; PO, oral route; SVT, supraventricular tachycardia.